Search Results
Your search for all items matches 34711 pages
Showing 13001 - 13050Are Younger Cancer Survivors More Susceptible to Financial and Food-Related Anxieties?
New research from the American Cancer Society published by Zheng et al in JNCCN–Journal of the National Comprehensive Cancer Network found that younger cancer survivors are more likely to experience significant financial strain for daily living necessities—such as food, housing, and monthly...
Risk of Cervical Cancer With Different Types of Intrauterine Devices
Patients who used copper intrauterine devices (IUDs) were found to have a lower risk of high-grade cervical neoplasms vs users of the levonorgestrel-releasing intrauterine system, according to a study published by Spotnitz et al in the journal Obstetrics & Gynecology. The study notes that more...
Adjuvant Etoposide/Cisplatin for Pathologic Stage II Nonseminomatous Germ Cell Tumors
In a single-center retrospective analysis reported by McHugh et al in the Journal of Clinical Oncology, two cycles of adjuvant etoposide plus cisplatin proved highly effective in patients with pathologic stage II nonseminomatous germ cell tumors. The combination also had acceptable toxicity and...
Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide for Patients With HER2-Negative Breast Cancer and a BRCA Mutation
In a phase II trial (INFORM; Translational Breast Cancer Research Consortium [TBCRC] 031) reported in the Journal of Clinical Oncology, Nadine Tung, MD, and colleagues found that neoadjuvant cisplatin did not improve pathologic complete response rate or residual cancer burden vs...
New ASCO Guideline Highlights the Management of Male Breast Cancer
THE ANNUAL INCIDENCE of male breast cancer in the United States is dwarfed by the rate among women. Yet, for the estimated 2,670 men who will be diagnosed with breast cancer this year, life-extending and life-enhancing treatments are crucial.1 To help reduce knowledge gaps and improve mortality and ...
Study Focuses on Role of Microbes in Pancreatic Cancer
Although bacteria are predominant in the gastrointestinal tract, they also reside on and in other parts of the body, including some unexpected places, such as malignant tumors. There are numerous reports of this phenomenon, but most have not identified a functional role for the microbes. In the...
FDA Pipeline: Breakthrough Therapy for NSCLC With Specific Mutation, Approval of Test for Cervical Cancer, and More
Over the past week, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to a bispecific antibody for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations; granted approval to a test for human...
Colorectal Cancer Statistics 2020 Published
The burden of colorectal cancer is shifting to younger individuals as incidence increases in young adults and declines in older age groups, according to Colorectal Cancer Statistics 2020. The median age of diagnosis dropped from 72 in 2001–2002 to 66 in 2015–2016. This finding and other data were...
Addition of Venetoclax to Cytarabine in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
In a phase I trial reported in The Lancet Oncology, Karol et al found that the combination of the BCL2 inhibitor venetoclax and the chemotherapeutic agent cytarabine with or without idarubicin produced responses in pediatric patients with relapsed or refractory acute myeloid leukemia. As noted by...
Evaluation of Genetic Testing in NCCN Criteria for Women With Breast Cancer
In a single-institution study reported in the Journal of Clinical Oncology, Yadav et al found that many women with breast cancer with germline pathogenic genetic variants do not qualify for genetic testing on current National Comprehensive Cancer Network® (NCCN®) hereditary testing criteria....
Conventionally Fractionated vs Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer: Long-Term Update
As reported in the Journal of Clinical Oncology by Avkshtol et al, the 10-year update of a single-center trial has confirmed the primary analysis of the study, showing no superiority in 5-year biochemical and/or clinical disease failure rate with moderate hypofractionated intensity-modulated...
Expert Point of View: Sue Sun Yom, MD, PhD
Sue Sun Yom, MD, PhD, Professor of Radiation Oncology & Otolaryngology–Head and Neck Surgery at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, said there is “reasonableness to further investigation” of the combination of programmed cell death...
Pembrolizumab Plus Radiotherapy Worthy of Further Study in Locally Advanced Squamous Cell Head and Neck Cancer
The combination of the checkpoint inhibitor pembrolizumab and definitive radiation therapy appears to be a safe and feasible option for patients with locally advanced head and neck cancer who are not eligible for cisplatin, according to data presented at the 2020 Multidisciplinary Head and Neck...
Annual Report to the Nation on the Status of Cancer Released
The Annual Report to the Nation on the Status of Cancer has found that cancer death rates continued to decline from 2001 to 2017 in the United States for all cancer sites combined. The report was published by Hensley et al in the journal Cancer. The annual report is a collaborative effort among the ...
Survival in Patients With Pancreatic Cancer Receiving Molecularly Matched Therapies
In a retrospective study reported in The Lancet Oncology, Michael J. Pishvaian, MD, and colleagues found that overall survival was better in patients with pancreatic cancer with actionable molecular alterations who received matched therapies compared with those who received only unmatched therapies ...
Bendamustine/Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis
In a phase II trial reported in the Journal of Clinical Oncology, Suzanne Lentzsch, MD, PhD, and colleagues found that the combination of bendamustine and dexamethasone showed activity in patients with relapsed/refractory systemic light-chain amyloidosis. As stated by the investigators, there...
Preoperative Letrozole for Postmenopausal Patients With Estrogen Receptor–Positive DCIS
In the phase II CALGB 40903/Alliance trial reported in the Journal of Clinical Oncology, E. Shelley Hwang MD, MPH, and colleagues found that preoperative letrozole was associated with beneficial imaging and biomarker changes in postmenopausal women with estrogen receptor (ER)-positive ductal...
Pulmonary Pathology of the Novel Coronavirus in Two Patients With Lung Cancer
We’ll begin this week by discussing an article that described the pulmonary pathology of the novel coronavirus, or COVID-19, which was found coincidentally in two patients undergoing surgery for lung cancer. We’ll also update you as to upcoming oncology meetings that have been canceled due to...
HAPLO2019: Advances in Haploidentical Transplantation and Other Novel Cellular Therapies
Now in its seventh year, the Haploidentical Transplant Symposium (HAPLO) continues to explore advances in haploidentical and other novel cellular therapies. The most recent of these meetings—HAPLO2019—met in Orlando, Florida, 2 days before the start of the 2019 American Society of Hematology (ASH)...
Expert Point of View: Daniel V.T. Catenacci, MD
Daniel V.T. Catenacci, MD, of the University of Chicago Medical Center and Biological Sciences, emphasized the value of the patient having microsatellite instability–high (MSI-H) status as a biomarker for immunotherapy. The analysis by Chao et al “highlights how well patients with MSI-H tumors do,...
Survival Benefits Achieved With Pembrolizumab in MSI-H and CPS ≥ 10 Gastric/Gastroesophageal Junction Cancer
Post hoc subanalyses of three KEYNOTE trials established the survival benefit of pembrolizumab in advanced gastric/gastroesophageal junction cancer with microsatellite instability–high (MSI-H) tumors or a programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥ 10 (ie, the number of...
Ho-166 Radioembolization After Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor Liver Metastases
In a single-center Dutch phase II trial reported in The Lancet Oncology, Braat et al found that holmium Ho-166 radioembolization produced responses in patients with neuroendocrine tumor liver metastases who had received peptide receptor radionuclide therapy with lutetium Lu-177 dotatate. Study...
Receipt of Adjuvant vs Neoadjuvant Chemotherapy and Start of Treatment in Patients With Breast Cancer
Research published by Melchior et al in Cancer Medicine has indicated that starting chemotherapy before surgery does not expedite the start or completion of treatment for breast cancer vs performing surgery first. “Increasingly, patients are given [neoadjuvant] chemotherapy…This is done for breast ...
Five-Year Survival for Cancers in Adolescents and Young Adults: 4-Decade Analysis
The 5-year survival rate for adolescents and young adults with cancer has significantly improved from 1975 to 2005 in the United States overall, but this was not the case for all types of cancer, according to a report published by Anderson et al in the Journal of the National Cancer Institute. “We ...
Association of Genomic Prostate Score With Adverse Pathology at Radical Prostatectomy After Initial Active Surveillance
In a study reported in the Journal of Clinical Oncology, Daniel W. Lin, MD, and colleagues found that the 17-gene Oncotype DX Genomic Prostate Score was not associated with the finding of adverse pathology among men with prostate cancer undergoing radical prostatectomy after initial active...
Preoperative Chemoradiotherapy vs Immediate Surgery for Pancreatic Cancer
In the Dutch phase III PREOPANC trial reported in the Journal of Clinical Oncology, Versteijne et al found that preoperative chemoradiotherapy did not improve overall survival vs immediate surgery in patients with resectable and borderline resectable pancreatic cancer. Benefits of preoperative...
FDA Approves Nivolumab/Ipilimumab for Pretreated Patients With Hepatocellular Carcinoma
On March 10, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with hepatocellular carcinoma who have been previously treated with sorafenib. CheckMate 040 Efficacy of the combination was...
Expert Point of View: Navid Hafez, MD, MPH
Ilixadencel is essentially a dendritic cell vaccine without preloaded antigens. In the MERECA study, ilixadencel produced “a great signal,” though this approach is still very experimental, said the study’s invited discussant, Navid Hafez, MD, MPH, of Yale Cancer Center. Dr. Hafez is a member of the ...
Off-the-Shelf Dendritic Vaccine Shows Benefit in Kidney Cancer
Ilixadencel is a cell-based, allogeneic, off-the-shelf product aimed at priming the anticancer immune response when injected intratumorally. The phase II MERECA study evaluated this allogeneic dendritic cell product given with sunitinib in 88 patients with metastatic renal cell carcinoma. The study ...
Study Examines Survival Rates in Pediatric and Young Adult Patients With Colon Cancer
According to research published by Andrea Hayes-Jordan, MD, FACS, and colleagues in the Journal of the American College of Surgeons, children and young adults with colon cancer are more likely to have shorter overall survival and recurrence-free survival than middle-aged adults. In a...
Evaluation of Different Methods of Biopsy for the Diagnosis of Prostate Cancer
In a study reported in The New England Journal of Medicine, Ahdoot et al found that combined use of magnetic resonance imaging (MRI)-targeted biopsy and 12-core systematic prostate biopsy led to enhanced detection of prostate cancers vs either approach alone in men with MRI-visible prostate...
Prognostic Value of Teratoma in Metastatic Nonseminomatous Germ Cell Tumor
In a single-institution retrospective study reported in the Journal of Clinical Oncology, Taza et al found that the presence of teratoma in primary tumor and postchemotherapy retroperitoneal lymph node dissection specimens was not a prognostic factor in patients with metastatic testicular germ cell ...
First-Line Cladribine With Concurrent or Delayed Rituximab for Hairy Cell Leukemia
In a phase II study reported in the Journal of Clinical Oncology, Robert J. Kreitman, MD, and colleagues found that achievement of minimal residual disease–free complete remission for patients with hairy cell leukemia was enhanced by adding concurrent rituximab to first-line cladribine; a lesser...
Help Patients Do More to Cope With Cancer-Related Pain
Relieving pain is an important part of cancer care, and each patient experiences pain differently. ASCO Answers offers two helpful products for managing cancer-related pain: a one-page fact sheet and an in-depth booklet. These resources help patients and their caregivers learn about: The...
QOPI Round 1 Now Open for Data Abstraction: Improve Quality Practice-Wide
ASCO’s Quality Oncology Practice Initiative (QOPI®) Round 1 of reporting is open for data abstraction. Round 1 will close on June 5, 2020, and final reports will be available approximately 4 weeks later. To get started, go to the registration portal at myqopi.asco.org/registration/login.aspx and...
Roles Are Reversed in ‘Personalized Medicine’ as Physicians Care for Parents With Cancer
As early-career oncologists, Rachna Shroff, MD, and Nina Shah, MD, offered patients a textbook bedside manner—personal interactions were limited, and emotions were rarely shared. “People talk about how, especially in oncology, the more you let [a patient] in, the more profoundly you feel losses,...
Medicaid Block Grants Threaten Beneficiary Access to Cancer Care
ASCO has released a position statement, “Block Grants in Medicaid & Their Impact on Cancer Care,” summarizing the Society’s concerns about the potential negative impact that block grants—proposals that establish annual limits on federal funding for Medicaid—could have on patients with cancer....
Conquer Cancer Honors Early-Career Cancer Researchers With Merit Awards
ASCO and Conquer Cancer, the ASCO Foundation®, congratulate the recipients of recent Conquer Cancer Merit Awards, which recognize oncology fellows’ and trainees’ high-quality research submitted in abstracts to an ASCO-sponsored or cosponsored meeting. These early-career researchers presented their...
Thirty-Three Oncology Practices Receive QOPI Certification From the Association for Clinical Oncology
Thirty-three practices received the Quality Oncology Practice Initiative (QOPI®) certification in the fourth quarter of 2019. The Association for Clinical Oncology applauds the work of these practices to ensure a better and healthier future. The following practices achieved QOPI certification or...
Conquer Cancer–Funded Researcher’s Pancreatic Cancer Study Highlighted in ASCO’s Clinical Cancer Advances 2020
The work of nine researchers who have previously received funding from Conquer Cancer is featured in ASCO’s Clinical Cancer Advances 2020. Visit CONQUER.ORG for more details. Advance of the Year: Refinement of Surgical Treatment At Massachusetts General Hospital, Janet Murphy, MD, is expanding...
Zelia M. Correa, MD, PhD, Joins Sylvester Comprehensive Cancer Center and Bascom Palmer Eye Institute
An expert in ocular oncology, Zelia M. Correa, MD, PhD, has joined Sylvester Comprehensive Cancer Center and Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine as Co-Director of the Ocular Oncology Service. Dr. Correa specializes in the diagnosis and treatment of eye...
Therapy Is Keeping My Metastatic Breast Cancer Manageable
Despite being vigilant about adhering to my annual schedule of screening mammography, in 2002, I was diagnosed with stage III triple-negative breast cancer. The diagnosis scared me, and I wondered if I was going to die. Determined to do what I could to survive the cancer, I underwent aggressive...
Susan Band Horwitz, PhD, Named Recipient of 2020 Szent-Györgyi Prize
The National Foundation for Cancer Research (NFCR) recently announced that Susan Band Horwitz, PhD, has been selected to receive the 2020 Szent-Györgyi Prize for Progress in Cancer Research. Dr. Horwitz is being recognized for pioneering the understanding, at the molecular level, of the mechanisms...
Reflections on a Career in Hematology/Oncology
I am a retired 82-year-old Hematologist/Oncologist who reads The ASCO Post regularly. I am writing to share some brief thoughts with the authors of two articles in the February 10, 2020 issue. First, I would address the article, A Hopeful Look Ahead in Oncology, written by Dan L. Longo, MD, MACP....
Building Onco-Primary Care to Close the ‘Black Hole’ in Cancer Survivorship Care
When the landmark report from the Institute of Medicine, From Cancer Patient to Cancer Survivor: Lost in Transition, was published in 2006, there were 10 million cancer survivors in the United States.1 Meant to raise awareness of the medical, functional, and psychosocial consequences of a cancer...
Former ASCO President Sandra M. Swain, MD, FACP, FASCO, Shares Highlights of a Noted Career
In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Sandra M. Swain, MD, FACP, FASCO, Professor of Medicine and Associate Dean for Research Development at Georgetown University Medical Center, and Vice President of MedStar Genetic Medicine at Medstar...
Attempt to Transform Venipuncture: A Brilliant Idea Made From Smoke and Mirrors
Venipuncture is the most commonly performed invasive procedure in hospitals daily. The risk of this procedure is nerve damage or an arterial nick. Of course, there are other possible issues, such as hematoma and injection-site infection. Then there’s dealing with caterwauling children and swooning...
Tazemetostat for Advanced Epithelioid Sarcoma
On January 23, 2020, tazemetostat was granted accelerated approval for the treatment of adults and pediatric patients aged 16 and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.1,2 Supporting Efficacy Data Approval was based on the finding of...
NCI Awards $9.1 Million Grant to Cedars-Sinai for Research on Dietary Fat and Liver Metastasis
A scientific team has been awarded a $9.1 million grant by the National Cancer Institute to study liver metastasis. The co-lead investigators, Neil Bhowmick, PhD, Director of the Cancer Biology Program, and Shelly Lu, MD, Women’s Guild Chair in Gastroenterology and Director of the Division of...
